Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. - sprookjes - yvandenbroek - TriplyDB

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

http://www.wikidata.org/entity/Q47387899

about

Topical steroid for chronic rhinosinusitis without polyps Mepolizumab versus placebo for asthma Omalizumab for asthma in adults and children Topical steroid for chronic rhinosinusitis without polyps Anti-IgE for chronic asthma in adults and children A review of omalizumab for the management of severe asthma Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review Effectiveness of omalizumab in severe persistent asthma under real-life conditions.Omalizumab: the evidence for its place in the treatment of allergic asthma Omalizumab in the treatment of asthma.Asthma-related comorbidities.Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.Omalizumab: Practical considerations regarding the risk of anaphylaxis.Omalizumab in children.Recommendation for optimal management of severe refractory asthma.Omalizumab in the management of patients with allergic (IgE-mediated) asthma.Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.Update on optimal use of omalizumab in management of asthma.Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study Omalizumab: clinical use for the management of asthma.Recent developments in asthma management Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.Molecular and cellular targets of anti-IgE antibodies.Emerging anti-inflammatory agents for allergic rhinitis.Omalizumab in the treatment of allergic respiratory disease.The Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and children Unusual asthma syndromes and their management Allergic rhinitis and its impact on otorhinolaryngology.The Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children.Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN).A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma Novel therapeutic interventions for allergic rhinitis.Inhibition of IgE Activity to Bind its High Affinity Receptor (FcεRIα) by Mouse Anti-IgE Cε3∼4 Monoclonal Antibody (QME5).Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma.The impact of comorbid atopic disease on asthma: clinical expression and treatment.

P2860

Q24185938-75432B5D-5CB7-45C3-A239-F704A0DCD522 Q24186306-A40E5170-27BE-4DE5-BC02-55EAC442817B Q24201145-3677F9B1-433B-4D36-AA14-5CEF6BAC9B20 Q24235014-45DDCE29-3D95-4F5B-9F41-D5E6496AAD99 Q24246484-951A86C6-E3E9-4971-BEA1-544AC818F317 Q26741315-2FAD1B81-8F5F-4AAE-A240-72C8CD1B031F Q28084119-A8B7FFF7-4967-481D-827F-90299A06AB46 Q30360362-224C3C4C-1B00-4A7F-855C-7C9335C3EAB4 Q30801642-6E37BA91-4BA9-4E18-ABC9-C2BE255EDE75 Q33894739-D60C7CA8-4C54-45C6-AC23-B9E567EF2DE2 Q33973970-CF2A181F-1628-40AF-91A8-E02C83A71ED3 Q34029374-35C87ED9-55F5-4899-82E0-9F8177884417 Q34195201-09D2C2F5-505E-4429-A1E1-AC006E4CD638 Q34412092-4A90AC60-F0F6-4DB4-A3D7-CD883BACF807 Q34426639-1E3B0364-2433-4AE1-9051-89846F4B7B9F Q34604574-6A1697E3-9A8A-4EBA-8D4E-EEE2CFAFC3CA Q34620187-68AC647B-64F4-4A31-88BB-04BA6B48B766 Q34623856-D3E6D491-594D-4981-85F9-E038CBE10A77 Q34627039-CCB4D7EF-6172-4C55-8B6F-0563BA83B4D5 Q35040868-3768E678-2211-4476-8323-EE7A0EB5F3EA Q35117827-CD49F8DD-E7FE-45EF-AFE3-494C2A3DA50C Q35536920-1B1B89EC-C46C-4E0C-A5F3-02EDC72F373A Q35768769-2181BB5F-E0AC-4D37-921A-880563FF120C Q35889211-8A9AE7E0-33EB-42EC-BB26-8C461D709A78 Q36055963-223A8334-A1DE-4326-B216-8E416A7B5185 Q36067978-999F7F17-988C-4317-B13E-9D1D6BECBFF3 Q36113704-99E1ACFD-1B09-4B17-B1E6-1F6D3D466E6B Q36169756-8EBE131C-A516-445D-9085-4191FD32FA12 Q36302823-9CC9C7C3-2B14-4FEB-BE61-50670A8A0712 Q36414178-212F7623-56DB-4DFD-B5B2-218A4099B216 Q36422663-F85FB976-F8E8-48C0-88C5-3C9C3C392F31 Q36443760-BF81B1C4-2A35-4F11-ADEC-82D712312C89 Q36469365-97147EDB-3610-470A-9B5D-D0538E811781 Q36566081-95542ADF-FE92-45BB-B349-7FDBEC825A1E Q36570549-575460D8-3551-47DC-B0E9-ECB1CE224DFE Q36642971-21ECC5A5-9004-47CD-8877-B61D07804F08 Q36654345-77DC8CD9-2428-4357-B64F-4E0B19E0FB2A Q36735617-BD055C96-7C7F-4092-8506-CC30ECAE216E Q36765775-01EB2FB8-FB7D-47AF-AC06-B66F261DEFCF Q36799761-F3C6752E-EE11-4895-8BA9-A5381B1DC3A8

P2860

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

http://www.wikidata.org/entity/Q47387899

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Efficacy and tolerability of a ...... tent allergic rhinitis: SOLAR.

@en

Efficacy and tolerability of a ...... tent allergic rhinitis: SOLAR.

@nl

type

label

Efficacy and tolerability of a ...... tent allergic rhinitis: SOLAR.

@en

Efficacy and tolerability of a ...... tent allergic rhinitis: SOLAR.

@nl

prefLabel

Efficacy and tolerability of a ...... tent allergic rhinitis: SOLAR.

@en

Efficacy and tolerability of a ...... tent allergic rhinitis: SOLAR.

@nl

P1433

Q47387899-3AFE35E1-A417-4039-8343-BDAAD894F29A

P1476

Q47387899-60538EDE-D3EB-45AE-83CA-53C5ECCB0F86

P2093

Q47387899-3812375F-4A02-4B95-AF96-4D0752C4AC67

Q47387899-4178B29A-5E5B-4E72-ACD1-C69D962ACCCC

Q47387899-646C5E89-8F3C-4998-99D7-266D2F0048A6

Q47387899-68C260DF-1CAE-4F89-B33D-58A48467ACA4

Q47387899-788CD6D4-8CB0-42B4-905D-8C544CBC5D9E

Q47387899-95400C61-BE8E-431F-BDF2-7594B35F75C8

Q47387899-B7506F3C-94B8-42FD-904A-5D452E2B2723

Q47387899-CD74B663-CDF5-4906-B302-33D3EA1ADA78

P2860

Q47387899-00AFFFB9-5C50-47EB-96F9-5BAB6E0032A1

Q47387899-482833C9-74C4-4B2B-813C-6B8C24D006DE

Q47387899-630D7671-D1B3-49E0-81CF-C0D0B49B0674

Q47387899-6D111469-97A5-4033-85E0-51FAB4C8D95C

Q47387899-6F14D43E-BE23-425F-B673-B664E784E928

Q47387899-7119F0C4-7526-40CC-97A0-538823DA0270

Q47387899-76AD99FD-172B-4E70-8D74-AA44F54E57C4

Q47387899-8F0BCD92-9827-4BCE-9182-9B3EB89759CF

Q47387899-9B655C86-1FBE-42E1-8287-19F6B142FF6B

Q47387899-B0EE03D6-C2DB-48EB-BF14-39080AA94763

P304

Q47387899-1EE2F635-3841-4120-933F-4BB5375FE50B

P31

Q47387899-E8BFA278-5C86-4922-815F-32510B843C9F

P356

Q47387899-20F1CE0D-BBB2-458F-B51C-838C3A53B608

P433

Q47387899-3FE6767F-713E-47B4-89A9-2F5FEAF017A6

P478

Q47387899-FEF384F9-4F65-4A5E-A4F8-38135BFB024F

P577

Q47387899-95F2E7A8-4EAF-45C0-8E7F-F39A21D8A8EC

P5875

Q47387899-CD891F82-3AA5-4358-9E8A-AC13511AB11C

P698

Q47387899-F1A2707D-102B-49DF-991D-27342CF43A12

P921

Q47387899-CD6C75E4-0EEC-49D1-AEC3-3F8D12D85FD7

P356

J.1398-9995.2004.00550.X

P1433

P1476

Efficacy and tolerability of a ...... tent allergic rhinitis: SOLAR.

@en

P2093

Blogg M

http://www.w3.org/2001/XMLSchema#string

Boulet LP

http://www.w3.org/2001/XMLSchema#string

Bousquet J

http://www.w3.org/2001/XMLSchema#string

Fox H

http://www.w3.org/2001/XMLSchema#string

Hedgecock S

http://www.w3.org/2001/XMLSchema#string

Humbert M

http://www.w3.org/2001/XMLSchema#string

Surrey K

http://www.w3.org/2001/XMLSchema#string

Vignola AM

http://www.w3.org/2001/XMLSchema#string

P2860

Quality of life in allergic rhinitis and asthma. A population-based study of young adults.

Treating the allergic patient: think globally, treat globally.

Allergy: a global problem. Quality of life.

Management of asthma in adults: current therapy and future directions

Rhinitis and asthma: evidence for respiratory system integration.

Links between rhinitis and asthma.

Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study.

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

Intranasal steroids and the risk of emergency department visits for asthma.

P304

709-717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1398-9995.2004.00550.X

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8525690

http://www.w3.org/2001/XMLSchema#string

P698

15180757

http://www.w3.org/2001/XMLSchema#string

P921